Abveris is a contract lab that uses genetically engineered in vivo systems for the discovery of antibodies in tight timelines. Our hybridoma discovery platform technology is anchored on an immunogenetically-optimized rodent system. We deliver antibodies to targets, and individual epitopes on those targets, that cannot be found in natural in vivo systems. Creating Antibodies with Custom Specificities The limiting factor in most in-vivo antibody discovery platforms is the diversity of the immune response of the host animal. Abveris uses a proprietary rodent that has been engineered to express a more diverse antibody repertoire than regular animals. This enables the discovery of antibodies with specificities that cannot be found in other in-vivo systems. When well-designed screening methods are applied to the large panel of hybridomas discovered, optimal antibodies are delivered. A wide range of screening methods and assay development capabilities are available. Our optimized system has allowed Abveris to accelerate the timeline for delivery of monoclonal hybridoma cell lines in only 60 days. Abveris’s platform can deliver antibodies to targets and epitopes that cannot be found in natural immune systems.
Royalty/milestone free, rapid delivery and you can expect antibodies to novel epitopes.
Panels of custom-screened mAbs delivered against a wide variety of target types. Difficult targets are welcome.
Biomolecular Interaction Analysis Services
Abveris, Inc has not received any reviews.
Abveris, Inc has not received any endorsements.